JP2025508868A - ヒトプログラニュリンに対する完全ヒトモノクローナル抗体 - Google Patents

ヒトプログラニュリンに対する完全ヒトモノクローナル抗体 Download PDF

Info

Publication number
JP2025508868A
JP2025508868A JP2024550558A JP2024550558A JP2025508868A JP 2025508868 A JP2025508868 A JP 2025508868A JP 2024550558 A JP2024550558 A JP 2024550558A JP 2024550558 A JP2024550558 A JP 2024550558A JP 2025508868 A JP2025508868 A JP 2025508868A
Authority
JP
Japan
Prior art keywords
antibody
cancer
seq
chain variable
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508868A5 (https=
Inventor
ジネット セレーロ
Original Assignee
エー アンド ジー ファーマシューティカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エー アンド ジー ファーマシューティカル，インコーポレイテッド filed Critical エー アンド ジー ファーマシューティカル，インコーポレイテッド
Publication of JP2025508868A publication Critical patent/JP2025508868A/ja
Publication of JP2025508868A5 publication Critical patent/JP2025508868A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oncology (AREA)
JP2024550558A 2022-02-24 2023-02-23 ヒトプログラニュリンに対する完全ヒトモノクローナル抗体 Pending JP2025508868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263313304P 2022-02-24 2022-02-24
US63/313,304 2022-02-24
PCT/US2023/063169 WO2023164581A2 (en) 2022-02-24 2023-02-23 Fully human monoclonal antibodies against human progranulin

Publications (2)

Publication Number Publication Date
JP2025508868A true JP2025508868A (ja) 2025-04-10
JP2025508868A5 JP2025508868A5 (https=) 2026-03-04

Family

ID=87766907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550558A Pending JP2025508868A (ja) 2022-02-24 2023-02-23 ヒトプログラニュリンに対する完全ヒトモノクローナル抗体

Country Status (6)

Country Link
US (1) US20250154237A1 (https=)
EP (1) EP4482861A2 (https=)
JP (1) JP2025508868A (https=)
KR (1) KR20250070618A (https=)
CN (1) CN119156399A (https=)
WO (1) WO2023164581A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024251974A1 (en) * 2023-06-09 2024-12-12 Calabrese Emma Methods of treating colorectal cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2724975T3 (es) * 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
WO2016187354A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
CN108196061B (zh) * 2017-12-18 2020-08-28 陕西师范大学 一种基于单克隆抗体检测人pgrn的双夹心elisa试剂盒

Also Published As

Publication number Publication date
WO2023164581A2 (en) 2023-08-31
KR20250070618A (ko) 2025-05-20
EP4482861A2 (en) 2025-01-01
US20250154237A1 (en) 2025-05-15
WO2023164581A3 (en) 2023-11-09
CN119156399A (zh) 2024-12-17

Similar Documents

Publication Publication Date Title
US12441795B2 (en) Anti-ROR1 antibodies and preparation method and uses thereof
CN106459199B (zh) 抗-egfrviii抗体及其用途
JP6326137B2 (ja) 抗ｈｅｒ２抗体及びその結合体
JP7726534B2 (ja) 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途
CN117897407A (zh) 抗Nectin-4抗体、药物缀合物及其制备方法和用途
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
WO2020119728A1 (zh) 抗人白细胞介素5(il-5)单克隆抗体及其应用
KR20230079409A (ko) 항-cd3 항체 및 이의 용도
CN113227142A (zh) 抗pd-1抗体及其用途
JP7270944B1 (ja) 抗ｃａｄｍ１抗体またはその抗原結合断片
US12534541B2 (en) Anti-PTK7 antibody and uses thereof
US20240352122A1 (en) Anti-cd48 antibodies, antibody drug conjugates, and uses thereof
TWI846095B (zh) 抗cd47-cldn18.2雙特異性抗體及其用途
JP2023103439A (ja) 固形腫瘍の治療に有益な抗体およびその抗体－薬物コンジュゲート並びにこれらを含む抗がん剤
US20240228658A1 (en) Anti-5t4 antibodies and uses thereof
US20250154237A1 (en) Fully human monoclonal antibodies against human progranulin
CN120424212A (zh) 抗FGFR2b抗体及抗体药物偶联物
US20260124316A1 (en) Fully human monoclonal antibodies against human her-2 and methods for using the same
RU2846737C2 (ru) Анти-нектин-4 антитело, конъюгат лекарственного средства, и способ его получения, и его применение
US20240262899A1 (en) Anti-cith3 antibodies and uses thereof
JP7769635B2 (ja) 抗ｃｄ１９抗体及びその使用
WO2025131063A1 (en) Antibody drug conjugates targeting b7-h3 and trop2 and the use thereof
WO2024081905A2 (en) Fully human monoclonal antibodies against human her-2
WO2025039809A1 (zh) 抗ror1抗体及其用途
CN118791612A (zh) 靶向cd26的抗原结合蛋白及其药物应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260224